Bacterial outer membrane

Spero Therapeutics Announces Positive Topline Results from Phase 1 Bronchoalveolar Lavage Clinical Trial of SPR206, A Novel Intravenous Next Generation Polymyxin Antibiotic for the Treatment of Multi-drug Resistant Gram-Negative Infections in the Hospital

Retrieved on: 
Wednesday, February 16, 2022

CAMBRIDGE, Mass., Feb. 16, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), today announced topline findings from its Phase 1 bronchoalveolar lavage (BAL) clinical trial of SPR206, an intravenously (IV)-administered next-generation polymyxin product candidate. SPR206 was derived from Spero’s potentiator platform and is in development to treat serious multi-drug resistant (MDR) gram-negative infections in the hospital setting.

Key Points: 
  • SPR206 was derived from Speros potentiator platform and is in development to treat serious multi-drug resistant (MDR) gram-negative infections in the hospital setting.
  • The Phase 1 BAL study evaluated the safety and pharmacokinetics (PK) of SPR206 when administered at 100 mg, three times daily.
  • Together with our prior Phase 1 and pre-clinical data, we look forward to engaging with regulators as we plan the continued development of SPR206.
  • The Phase 1 BAL clinical trial was an open-label study designed to enroll 30 healthy volunteers into five cohorts.

Pew Funds Six Teams to Advance Innovative Biomedical Research

Retrieved on: 
Wednesday, September 15, 2021

These scientistsalumni of Pew's biomedical programs in the United States and Latin Americawill partner on interdisciplinary research to tackle some of the most pressing questions in human biology and disease.

Key Points: 
  • These scientistsalumni of Pew's biomedical programs in the United States and Latin Americawill partner on interdisciplinary research to tackle some of the most pressing questions in human biology and disease.
  • "The COVID-19 pandemic has underscored the critical role innovative biomedical research plays in addressing global health problems," said Molly Irwin, vice president for research and science at The Pew Charitable Trusts.
  • For more than 35 years, Pew has encouraged collaboration among its diverse community of biomedical scientists, culminating in the launch of the Innovation Fund in 2017.
  • The fund's award criteria were developed to promote synergy among program alumni, motivating researchers to collaborate on new proposals.